News headlines about NeoGenomics (NASDAQ:NEO) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. NeoGenomics earned a media sentiment score of 0.22 on Accern’s scale. Accern also assigned media headlines about the medical research company an impact score of 46.8162801970963 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the media headlines that may have effected Accern’s scoring:

A number of equities research analysts have recently weighed in on NEO shares. Royal Bank of Canada set a $23.00 target price on NeoGenomics and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. BidaskClub downgraded NeoGenomics from a “buy” rating to a “hold” rating in a report on Thursday, December 21st. Scotiabank set a $22.00 target price on NeoGenomics and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. CIBC set a $19.00 target price on NeoGenomics and gave the stock a “neutral” rating in a report on Wednesday, January 3rd. Finally, Zacks Investment Research raised NeoGenomics from a “sell” rating to a “hold” rating in a report on Friday, February 23rd. Five equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $15.83.

Shares of NeoGenomics (NASDAQ NEO) opened at $8.66 on Friday. NeoGenomics has a twelve month low of $7.08 and a twelve month high of $11.63. The company has a current ratio of 2.14, a quick ratio of 1.99 and a debt-to-equity ratio of 0.57. The firm has a market capitalization of $682.68, a price-to-earnings ratio of -61.85, a PEG ratio of 4.72 and a beta of 0.47.

NeoGenomics (NASDAQ:NEO) last posted its earnings results on Wednesday, February 21st. The medical research company reported $0.04 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.02 by $0.02. NeoGenomics had a positive return on equity of 4.37% and a negative net margin of 1.37%. The company had revenue of $67.79 million during the quarter, compared to the consensus estimate of $66.32 million. During the same quarter last year, the firm earned $0.05 earnings per share. The company’s revenue was up 12.1% on a year-over-year basis. research analysts forecast that NeoGenomics will post 0.09 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was first published by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at

NeoGenomics Company Profile

NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.

Insider Buying and Selling by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with's FREE daily email newsletter.